Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.97 USD | -0.44% | +0.11% | -20.20% |
Mar. 01 | Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. | CI |
Feb. 26 | Transcript : Theravance Biopharma, Inc., Q4 2023 Earnings Call, Feb 26, 2024 |
Evolution of the average Target Price on Theravance Biopharma, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Theravance Biopharma, Inc.
HC Wainwright | |
SVB Securities LLC | |
JPMorgan Chase | |
SVB Leerink | |
Baird | |
Morgan Stanley | |
Needham & Co. | |
Cowen | |
BofA Securities | |
Evercore ISI |
EPS Revisions
- Stock
- Equities
- Stock Theravance Biopharma, Inc. - Nasdaq
- Consensus Theravance Biopharma, Inc.